U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085676) titled 'Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases' on May 06.
Brief Summary: A Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease.
Study Start Date: Sept. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus (SLE)
Systemic Sclerosis (SSc)
Idiopathic Inflammatory Myopathy (IIM)
Rheumatoid Arthritis (RA)
Intervention:
BIOLOGICAL: HBI0101 CART
HBI0101 CART is defined as au...